Literature DB >> 17238180

Survival after hepatic resection in metastatic colorectal cancer: a population-based study.

Linda C Cummings1, Jonathan D Payes, Gregory S Cooper.   

Abstract

BACKGROUND: Hepatectomy is the standard of care for patients with colorectal cancer who have isolated hepatic metastases; however, the long-term survival benefits of hepatectomy in this population have not been characterized well outside of case series. For the current study, a population-based database was used to compare the survival of patients with liver metastases from colorectal cancer who did and did not undergo hepatectomy.
METHODS: Patients aged >or=65 years with incident colorectal cancer who were diagnosed from 1991 to 2001 were identified from the linked Surveillance, Epidemiology, and End Results (SEER)-Medicare database. Liver metastasis diagnoses, colorectal resections, and hepatectomies were identified from hospital, outpatient, and physician-supplier claims. Patients who did not undergo colorectal resection were excluded. Five-year survival from the time of cancer diagnosis was determined by the Kaplan-Meier method. Cox proportional hazards models were used to evaluate survival.
RESULTS: Among 13,599 patients who were identified with incident colorectal cancer and liver metastases, 7673 patients (56.4%) presented with stage IV disease, and the remaining patients presented with earlier stage disease and developed subsequent metastases. Only 833 patients (6.1%) in the cohort underwent hepatic resection, and their 30-day mortality rate was 4.3%. The 5-year survival was 32.8% among patients who underwent hepatic resection, compared with 10.5% among patients who did not undergo hepatic resection (P < .0001), and better survival was observed in the subset of patients who presented initially with disease in stages I through III. In a Cox model, which was controlled for age, sex, race, comorbidities, and stage at presentation, lack of hepatic resection was associated with a 2.78-fold increased risk of death.
CONCLUSIONS: Although hepatectomy rates among patients with colorectal cancer were low, hepatic resection was associated with improved survival.

Entities:  

Mesh:

Year:  2007        PMID: 17238180     DOI: 10.1002/cncr.22448

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  101 in total

1.  A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer.

Authors:  Sam J Lubner; Noelle K Loconte; Kyle D Holen; William Schelman; James P Thomas; Alcee Jumonville; Jens C Eickhoff; Songwon Seo; Daniel L Mulkerin
Journal:  Clin Colorectal Cancer       Date:  2010-07       Impact factor: 4.481

Review 2.  [Interventional procedures for hepatic metastases].

Authors:  T Helmberger
Journal:  Chirurg       Date:  2010-06       Impact factor: 0.955

Review 3.  Lesion discrimination with breath-hold hepatic diffusion-weighted imaging: a meta-analysis.

Authors:  Zhi-Guang Chen; Li Xu; Si-Wei Zhang; Yan Huang; Rui-Huan Pan
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

4.  Liver biopsy in a district general hospital: changes over two decades.

Authors:  Wing-Kin Syn; Caroline Bruckner-Holt; Adam Farmer; Sarah Howdle; Jeffrey Bateman
Journal:  World J Gastroenterol       Date:  2007-10-28       Impact factor: 5.742

5.  Surgical specialization and operative mortality in hepato-pancreatico-biliary (HPB) surgery.

Authors:  Nicholas G Csikesz; Jessica P Simons; Jennifer F Tseng; Shimul A Shah
Journal:  J Gastrointest Surg       Date:  2008-07-09       Impact factor: 3.452

6.  Prognostic factors for peritoneal carcinomatosis originating from colorectal cancer: an analysis of 921 patients from a multi-institutional database.

Authors:  Heita Ozawa; Kenjiro Kotake; Hirotoshi Kobayashi; Hirotoshi Kobayashi; Kenichi Sugihara
Journal:  Surg Today       Date:  2014-09       Impact factor: 2.549

7.  Combined therapeutic efficacy of 188Re-liposomes and sorafenib in an experimental colorectal cancer liver metastasis model by intrasplenic injection of C26-luc murine colon cancer cells.

Authors:  Ya-Jen Chang; Wei-Hsin Hsu; Chih-Hsien Chang; Keng-Li Lan; Gann Ting; Te-Wei Lee
Journal:  Mol Clin Oncol       Date:  2014-01-20

8.  Multi-institutional phase II study on the feasibility of liver resection following preoperative mFOLFOX6 therapy for resectable liver metastases from colorectal cancers.

Authors:  Satoshi Nagayama; Suguru Hasegawa; Koya Hida; Kenji Kawada; Etsuro Hatano; Kojiro Nakamura; Satoru Seo; Kojiro Taura; Kentaro Yasuchika; Takashi Matsuo; Masazumi Zaima; Akiyoshi Kanazawa; Hiroaki Terajima; Masaharu Tada; Yukihito Adachi; Ryuta Nishitai; Dai Manaka; Tsunehiro Yoshimura; Koji Doi; Takahiro Horimatsu; Akira Mitsuyoshi; Kenichi Yoshimura; Miyuki Niimi; Shigemi Matsumoto; Yoshiharu Sakai; Shinji Uemoto
Journal:  Int J Clin Oncol       Date:  2016-10-17       Impact factor: 3.402

9.  Accomplishments in 2008 in the management of curable metastatic colorectal cancer.

Authors:  René Adam; Emir Hoti; Gunnar Folprecht; Al B Benson
Journal:  Gastrointest Cancer Res       Date:  2009-09

10.  Simultaneous colorectal and hepatic procedures for colorectal cancer result in increased morbidity but equivalent mortality compared with colorectal or hepatic procedures alone: outcomes from the National Surgical Quality Improvement Program.

Authors:  Osama H Hamed; Neil H Bhayani; Gail Ortenzi; Jussuf T Kaifi; Eric T Kimchi; Kevin F Staveley-O'Carroll; Niraj J Gusani
Journal:  HPB (Oxford)       Date:  2012-12-27       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.